Novel latanoprost nanoemulsion, an alternative to traditional drops containing benzalkonium chloride: Study
Argentina: A new ophthalmic latanoprost nanoemulsion is significantly less cytotoxic on human conjunctival cells than ophthalmic latanoprost solution containing Benzalkonium chloride, states a recent study published in Graefe's Archive for Clinical and Experimental Ophthalmology.
Benzalkonium chloride (BAK), the most commonly used preservative in anti-glaucoma eye drops, inflicts damage to the ocular surface on long-term use. It is known to cause eye irritation, and symptoms of dry eyes and may affect the tear film and corneal surface. Thus, a novel anti-glaucoma formulation that avoids the use of BAK was developed to improve patient comfort and tolerability.
Author Julia Tau, Faculty of Medicine, University of Buenos Aires, Argentina, and colleagues conducted research to evaluate the cytotoxicity of this new Latanoprost nanoemulsion (BAK free) and compare it with an ophthalmic solution (containing BAK).
The research team used two different latanoprost eye drops one ophthalmic solution (LSc) containing BAK 0.02% and one ophthalmic nanoemulsion (LNe) with a soft preservative (potassium sorbate 0.18%). Human epithelial conjunctival cells were incubated for 15, 30, and 60 min with either LSc or LNe. The cytotoxicity was determined by an MTT assay. Cell death was measured by flow cytometry using annexin V–FITC and propidium iodide.
The key findings of the study are:
• The cells exposed to LNe maintained the viability of 80% to 90%, which was significantly higher versus the group with LSc (30%), at all time points during the study
• LNe group showed stable proportions of cell viability and apoptosis at all time points, whereas the LSc group had a time-dependent decrease in cell viability and an increase in cell necrosis.
On analyzing the study results, the author and team concluded that the new latanoprost nanoemulsion is significantly gentler on the cornea and conjunctiva than currently available BAK preserved latanoprost solutions, with levels of cytotoxicity equivalent to control. Further studies are warranted to evaluate the comparative efficacy of both.
Tau, J., Passerini, M.S., del Papa, M. et al. A novel ophthalmic latanoprost 0.005% nanoemulsion: a cytotoxicity study. Graefes Arch Clin Exp Ophthalmol Published 11 January 2022 Issue DateJune 2022
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.